137 Results
Sort By:
Published on April 21, 2020
Molecular diagnostics and bioinformatics company OpGen which focuses on infectious disease, announced an investigator-initiated collaboration with Karolinska Institutet, Sweden, to identify bacterial co-infections in patients admitted to the ICU for COVID-19 pneumonia. High-risk COVID-19 patients, which includes the elderly and others with co-morbidities including diabetes and obesity, are also at…
Published on April 21, 2020
With the UK government reportedly now sitting on £millions-worth of imported coronavirus antibody test kits that proved unreliable under scrutiny, home-grown diagnostics firm Mologic is poised to start commercial-scale manufacture and rollout of both its laboratory ELISA, and low-cost—potentially £1 per test—lateral flow point-of-need coronavirus antibody tests, which could be…
Published on April 20, 2020
While the bulk of the diagnostics efforts for the COVID-19 pandemic have focused initially on identifying patients with the disease, there is now also a growing effort to develop serology testing to identify people who have developed antibodies to the disease. This form of testing is a necessary next step…
Published on April 8, 2020
Diagnostics developer Nanomix today announced that it will receive roughly $570,000 from the Biomedical Advanced Research and Development Authority (BARDA), part of the office tasked with preparedness and response at the U.S. Department of Health and Human Services for the development and testing of COVID-19 point-of-care tests., which provides results…
Published on April 8, 2020
BillionToOne Co-Founder and CEO Oguzhan Atay, Ph.D. Precision diagnostics developer BillionToOne said it has developed the protocol for a novel COVID-19 test that is accurate and cost-effective enough to fulfill the crush of demand for tests—more than one million testing capacity per day in the U.S. alone. The…
Published on April 2, 2020
Diagnostics developer and life science research company Adaptive Biotechnologies and Amgen announced today a partnership to discover and develop fully human neutralizing antibodies for the possible prevention and treatment of COVID-19. The collaboration will leverage together Adaptive’s proprietary immune medicine platform for the identification of virus-neutralizing antibodies targeting SARS-CoV-2 with…
Published on March 30, 2020
Abbott said it will make available this week its ID NOW™ COVID-19 test designed to deliver positive results for detecting nucleic acid from SARS-CoV-2 in five minutes, and negative results in 13 minutes, following Emergency Use Authorization from the FDA—results that according to the company make it the fastest available…
Published on March 24, 2020
A U.K.-based division of clinical diagnostics company Novacyt announced Monday that it was granted an Emergency Use Authorization (EUA) by the FDA for its COVID-19 diagnostic test. Developed by the company’s molecular diagnostics division Primerdesign, the test is available for immediate distribution to hospitals and laboratories in the U.S. The…
Published on March 20, 2020
Biodesix said it will partner with Bio-Rad Laboratories to bring a COVID-19 test using Bio-Rad’s Droplet Digital PCR (ddPCR) system to the FDA for an Emergency Use Authorization (EUA) approval. EUA approval would enable the companies to begin testing in the U.S. “Biodesix is committed to moving as quickly as…
Published on September 13, 2021
Oxford Nanopore, the pioneer developer of DNA/RNA nanopore sensing tools that include its pocket-sized MinION DNA/RNA sequencer, has disclosed plans for an initial public offering that could value the company at a reported £4 billion ($5.5 billion). Oxford Nanopore seeks to trade its shares on the London Stock Exchange. “Ever…
Published on September 28, 2020
Molecular methods of diagnosing diseases promise fast and accurate approaches for an array of conditions. While many molecular diagnostics look for mutations in DNA, an increasing number analyze a sample’s RNA, and those are explored here. Manufacturers offer a variety of RNA-based diagnostics, and academic scientists continue to explore new…
Published on June 15, 2020
COVID-19 testing has been a failure in the United States since the very onset of the outbreak. Sick patients have had to wait for hours in lines outside hospitals or overnight in their cars. Those who were able to get their noses swabbed are subjected to a second wait for…
Published on April 23, 2024
A big challenge with the SARS-CoV-2 virus, which causes COVID, is that it regularly generates variants. Now, a new targeted RNA consensus sequencing method (tARC-seq) can accurately determine SARS-CoV-2 mutation frequency and types, both in cell culture and clinical samples, according to researchers at Baylor College of Medicine and collaborating…
Published on April 3, 2024
SAN DIEGO—Eric Topol, MD, renowned cardiologist and Director of the Scripps Research Translational Institute, believes that the use of artificial intelligence (AI) will be “the biggest transformation in the history of medicine.” As a keynote speaker at the 31st annual Precision Med TRI-CON meeting, hosted by Cambridge Healthtech Institute, Topol…
Published on December 21, 2023
By Nava Whiteford The first thing I imagine when asked to write about the future of sequencing is a young researcher gliding to her lab bench on a hoverboard, where she presses a single bright button labeled “Sequlite 10000.” A blur of motion and computer graphics engulf the lab. Ten…